The AI first Genomics Company
Beyond AI, we believe that AI meets biology is the biggest opportunity of the 21st century. We are the software company designing custom mRNA vaccines for dogs.
This is only just the beginning.
Our mission
Why Gamgee exists
Biology is becoming increasingly readable. We can sequence genomes, compare healthy and diseased tissue, observe gene expression, map immune activity, and watch cellular populations change over time.
But treatment is still usually chosen from a small menu designed for broad patient groups. Gamgee begins with the molecular state of one patient and designs around what is happening now.
Read the patient's biology at molecular resolution rather than infer it from population averages.
Understand disease as a changing causal system, including uncertainty and competing explanations.
Design the intervention the present biological state demands, rather than force every problem into one modality.
Measure the outcome so the next intervention and the system that produced it can improve.
Genomics is how Gamgee begins to understand the system. Bioengineering is how we change it. Artificial intelligence connects the two.
Our origin
Gamgee began with Rosie.
When Rosie developed cancer, we used genomics, artificial intelligence, and programmable medicine to turn the molecular features of her tumour into a treatment designed specifically for her.
Her treatment showed that an end-to-end personalised workflow could be built: sample, sequence, analyse, design, manufacture, administer, and measure.
That first treatment was not the destination. It exposed the path.
Read Rosie's story →Why cancer comes first
Cancer mutates, evolves, changes state, reshapes its environment, evades immune surveillance, and develops resistance to fixed treatments. It concentrates many of genomic medicine's hardest problems into one disease.
Understanding and controlling it requires advances in molecular sensing, causal models of changing cell populations, personalised intervention design, immune engineering, delivery, rapid manufacturing, and clinical measurement.
They are patients, not disposable models. Their cancers arise naturally inside functioning immune systems and evolve over time. Serving them responsibly requires personalised genomic medicine to become repeatable, manufacturable, and clinically useful.
AI-first from the ground up
AI-first does not mean adding a chatbot to a conventional laboratory.
Every paper, claim, dataset, patient sample, molecular design, experiment, failure, manufacturing run, and clinical outcome should become part of a connected research memory.
Search across disciplines and challenge published claims.
Construct competing causal explanations and expose uncertainty.
Choose the smallest experiment capable of deciding between them.
Propose an intervention, interpret the result, and revise the model.
Continue the loop with a research memory that grows rather than resets.
Humans set the mission, define the evidence required, exercise scientific judgment, and enforce ethical and safety boundaries. Machines conduct more of the search, synthesis, experimental design, and iteration.
The central bet is that a sufficiently capable research system, connected to experimental and clinical reality, can discover fundamentally new ways of intervening in biology.
The first product, not the final identity
They are valuable treatments in their own right and establish the practical foundation of the company: sequencing, analysis, design, manufacturing, clinical delivery, and response measurement.
Gamgee should not be defined by one therapeutic modality. The enduring company is the system that turns molecular state into intervention and becomes faster, cheaper, and more capable with every cycle.
Progress must show up in speed and cost. Custom medicine should move from an artisanal process toward an automated system that can reach far more patients.
Long-term operating goals
These are development targets, not current product availability, turnaround, or pricing.
From cancer to biological repair
The tools built to understand, reach, and control malignant cells may eventually address other forms of biological damage.
Aging is not one disease. It is many failures accumulating over time. Gamgee's longer-term aim is to make those failures legible and repairable one by one, while restoring function without weakening the controls that protect against cancer.
We begin with an urgent commitment to dogs with cancer. We are building toward a broader system for biological repair.
Build with us
Gamgee sits at the intersection of software, genomics, immunology, RNA engineering, manufacturing, veterinary oncology, and clinical research.
We want to work with people and institutions who believe biology can become more understandable, programmable, and repairable without losing scientific rigor or respect for the patient.
We are especially interested in hearing from: